2019 Sino Cell Technologies Embarked on its International Cooperation through Transfer of Immune Technology from Japan
Sino Cell Technologies obtained the license of the immune cell therapy, which is developed by Dr. Hiroshi Terunuma and patented in Japan. After taking the whole blood from a patient, peripheral blood mononuclear spheres are separated for cultivation and proliferation of NK cells. The activation degree of the NK cells are assessed before further cultivating, proliferating and differentiating strong NK cells, and ensuring their amount and activity. At the end, the NK cells are transfused back to the patient to fight against cancer.
Dr. Joann Kurtzberg, an internationally renowned expert in the application of umbilical cord blood stem cell, came to Taiwan and visit The Ministry of Health and Welfare in 2018.
The Ministry of Health and Welfare amended "Regulations Governing the Application of Specific Medical Examination Technique and Medical Device" on September 6. After the amendment was passed, cell therapy is in the mainstream of the medical application. The amendment also helps the cooperation between the medical institutions and the biotechnology companies that focused on the research and development or technical cooperation and the medical institutions of cell therapy for a long time. Hope to benefit Taiwan patients who need cellular therapies.
Sino Cell and Duke University cooperate to create a "cord blood medical platform for regenerative medicine" in 2017.
Elaine Hsieh , board member of The Cord Blood Association (CBA) and chairman of Sino Cell Technologies Co.Ltd , will actively seek international medical technology cooperation with Dr. Joann Kurtzberg, a professor of Duke University. They will collaborate the Taiwan government and medical institutions to create an "Umbilical Cord Blood Stem Cell Medical Research Platform" for no effective treatment diseases, such as cerebral palsy, autism, etc. to have more opportunities by cord blood research achievement.
Sino Cell Technologies, Ltd. (SCT) became the member bank of Cord Blood Association (CBA). In 2016 CBA member banks include Cord Blood Registry (CBR, the No.1 family bank in the US), PerkinElmer Viacord, New York Blood Center, Stem Cell Institute, Inc (Tokyo, Japan) and other family and public banks from all over the world. Incumbent president is Dr. Joanne Kurtzberg, an internationally renowned expert in umbilical cord blood banking and transplantation from Duke University, School of Medicine. As a member of CBA, SCT has proved its technology in line with global standards. In the future, SCT will work with CBA closely in cord blood innovations, products, technologies, market expansion and services.
Received exclusive U.S. Patent for〝Serum-free Culture Medium〞.Patent Number US 8762074 B2 in 2014.
Created the〝Peripheral Blood Stem Cell Bank〞and was audited and authorized by the Ministry of Health and Welfare to comply with the Regulations for Administration on Human Organ Bank in 2013.
Combined with SinoPac Life Insurance Agent Co. and Cathay Life Insurance to offer Taiwan’s first〝Health Insurance for Umbilical Cord Blood Transplantation (UCBT) 〞in 2012.
Industry-academic collaboration with Yuan Ze University on the development of〝Isolation and ex vivo Expansion of Vascular Endothelial Precursor Cells in Umbilical Cord Blood〞in 2010.
Signed a contract with National Yang Ming University and became Taiwan’s first UCB stem cell company to be authorized for the patented cell culture technology for 〝Umbilical Cord Mesenchymal Stem Cells〞in 2009 .
Collaborated with Taipei Medical University on〝The Establishment for Preservation and Quality Control Technology of Umbilical Cord and Amniotic Derived Mesenchymal Stem Cells〞.
Collaborated with the medical teams from CGMH and NTUH to complete Taiwan’s first case on〝Treatment of Cerebral Palsy with Autologous Umbilical Cord Blood〞in 2007.
National Innovation Award was granted to the self-developed 〝Portable Thermostatic Transporting Box for Umbilical Cord Blood〞in 2006.
In 2005,The〝HSC ex vivo Expansion Technology〞was awarded international patent application number.
The first institution in Taiwan to introduce the Taylor-Wharton’s LABS-80K large LN2 storage system since 2004.
In 2003,The〝Serum-free Culture and Directed Differentiation of Umbilical Cord Blood-Derived Mesenchymal Stem Cells〞was granted SBIR funding by the Ministry of Economic Affairs.
In 2002,The research and development project 〝Analytic System for the ex vivo Expansion of Hematopoietic Stem Cells〞was granted Small Business Innovation Research (SBIR) funding by the Ministry of Economic Affairs.
In 2001,Established the〝Sino Cell Stem Cell Cryopreservation Center〞at the Bioresource Collection and Research Center (BCRC) of the FIRDI.